$17 billion, buy buy buy! Head pharmaceutical companies snowball!

On October 5, Pfizer announced the completion of the acquisition of Global Blood Therapeutics (GBT) at a transaction value of $5.
4 billion at a price of $
68.
50 per share of Global Blood Therapeutics.
It's another step after Pfizer completed its acquisition of Biohaven Pharmaceuticals on Oct.
3: Pfizer acquired all outstanding shares of Biohaven that it did not own for $148.
50 per share in cash, for a total consideration of approximately $11.
6 billion.

As a result of the acquisition, Biohaven became a wholly owned subsidiary
of Pfizer.

Generous! Pfizer acquires GBT for $5.
4 billion, adding to the rare field of hematology! GBT is a biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments, starting with sickle cell disease (SCD), bringing hope
to underserved patient populations.
The acquisition reinforces Pfizer's commitment to SCD, which has been in the rare field of hematology for 30 years
.
GBT brings a pipeline portfolio that has the potential to meet the critical needs
of this unmet patient population.
GBT discovered and developed Oxbryta® (voxelotor), a FIC drug
that directly targets the root cause of SCD.
In addition, GBT's promising preclinical and clinical research pipelines focused on SCD include GBT021601 (GBT601) and inclaclumab, both of which have been recognized by the U.
S.
Food and Drug Administration (FDA) as
orphan drugs and rare pediatric diseases.
Aamir Malik, Chief Business Innovation Officer and Executive Vice President of Pfizer, said: "As GBT's talent, portfolio and pipelines become part of Pfizer, we look forward to accelerating innovation and rapidly bringing multiple potential BIC drugs
to patients with sickle cell disease.
"Pfizer is committed to addressing the unmet needs
of the sickle cell disease patient population.
We are excited
about these potential breakthroughs and opportunities to change the lives of these patients.
"SCD is a lifelong and devastating hereditary blood disease that affects millions of people worldwide, mainly people of African, Middle Eastern and South Asian descent
.
Pfizer will continue to strengthen the company's shared commitment and engagement with
the SCD community.
The GBT pipeline is as follows:

On October 3, Pfizer announced the completion of its acquisition of Biohaven, a manufacturer of NURTEC®ODT (rimegepant), an innovative migraine therapy approved for acute treatment and prevention of episodic migraine in adults
。 This acquisition brings Pfizer a promising range of calcitonin-related peptide (CGRP) receptor antagonists, including: Rimegepant:--NURTEC®ODT, approved in the U.
S.
, for the prophylactic treatment of migraine in adults with or without aura and episodic migraine--VYDURA approved in the European Union, the trade name VYDURA®, Zavegepant for acute treatment of migraine in adults with or without warning and preventive treatment of adult episodic migraine with or without migraines at least 4 episodes per month: -- New Drug Application (NDA) for intranasal sprays for acute treatment of migraine in an FDA review, PDUFA date is the first quarter
of 2023.
Pfizer, the preclinical CGRP asset pipeline, acquired all outstanding shares of Biohaven at a price of $148.
50 per share in cash, for a total consideration of approximately $11.
6 billion.

As a result of the acquisition, Biohaven became a wholly owned subsidiary
of Pfizer.

Source:

--

--

--

--